US 12,441,734 B2
Ferroptosis inhibitor and use therefor
Hitoshi Osaka, Shimotsuke (JP); Akihiko Miyauchi, Shimotsuke (JP); Eriko Jimbo, Shimotsuke (JP); and Mizuki Kobayashi, Shimotsuke (JP)
Assigned to JICHI MEDICAL UNIVERSITY, Tokyo (JP)
Appl. No. 18/710,113
Filed by JICHI MEDICAL UNIVERSITY, Tokyo (JP)
PCT Filed Nov. 14, 2022, PCT No. PCT/JP2022/042198
§ 371(c)(1), (2) Date May 14, 2024,
PCT Pub. No. WO2023/085420, PCT Pub. Date May 19, 2023.
Claims priority of application No. 2021-185384 (JP), filed on Nov. 15, 2021.
Prior Publication US 2024/0327420 A1, Oct. 3, 2024
Int. Cl. C07D 491/06 (2006.01); A61K 31/473 (2006.01); A61K 31/4741 (2006.01); C07D 221/18 (2006.01)
CPC C07D 491/06 (2013.01) [A61K 31/473 (2013.01); A61K 31/4741 (2013.01); C07D 221/18 (2013.01)] 13 Claims
 
1. A compound represented by the formula (I-1):

OG Complex Work Unit Chemistry
wherein
RN1 is methyl,
R1 is hydrogen,
both R2 and R3 are hydrogen,
R4 is hydroxyl,
R5 is selected from the group consisting of unsubstituted C1 to C9 alkoxy, C1 to C9 alkoxy substituted by at least one monovalent group selected from the group consisting of halogen, hydroxyl, and carboxyl, unsubstituted C7 to C20 arylalkyloxy, and C7 to C20 arylalkyloxy substituted by at least one monovalent group selected from the group consisting of halogen, hydroxyl, and carboxyl, with the proviso that methoxy and benzyloxy are excluded from R5, and
both R6 and R7 are hydrogen,
or a salt thereof, or a solvate of the compound or the salt.